Clinical Trial Update: Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the efficacy and safety of Repaglinide, Glurenorm, and Glucobay in Chinese subjects with Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glucobay (acarbose)
• Glurenorm (repaglinide)
• Repaglinide (Repaglinide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED